Refine
Year of publication
Language
- English (923)
Has Fulltext
- yes (923)
Is part of the Bibliography
- no (923)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (8)
- Heavy-ion collision (5)
- Collective Flow (4)
- Quark-Gluon Plasma (4)
- Jets (3)
- Jets and Jet Substructure (3)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- LHC (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- multiple myeloma (2)
- 900 GeV (1)
- ALICE (1)
- ALICE detector (1)
- Anti-nuclei (1)
- Boosted Jets (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Centrality Class (1)
- Centrality Selection (1)
- Collective Flow, (1)
- Colonisation (1)
- Contact precautions (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- European Society for Immunodeficiencies (ESID) (1)
- Fibre/foam sandwich radiator (1)
- Genomic instability (1)
- German PID-NET registry (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- IgG substitution therapy (1)
- Infection control (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Material budget (1)
- Minimum Bias (1)
- Molecular medicine (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-wire proportional drift chamber (1)
- Multidrug-resistant bacteria (1)
- NK cells (1)
- NKG2A blocking (1)
- Neural network (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb collisions (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- QCD (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quarkonium (1)
- Rapidity Range (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- adoptive cell therapy (1)
- anthropology (1)
- autologous stem cell transplantation (1)
- bortezomib (1)
- checkpoint inhibition (1)
- collaboration (1)
- dE/dx (1)
- detector (1)
- ectosomes (1)
- ethnographic knowledge production (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- guidelines (1)
- heavy ion experiments (1)
- induction regimen (1)
- interpretative authority (1)
- kidney (1)
- lenalidomide (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- primary immunodeficiency (PID) (1)
- quark gluon plasma (1)
- reflexivity (1)
- registry for primary immunodeficiency (1)
- renal failure (1)
- reproducibility (1)
- rigor (1)
- standardization (1)
Institute
- Physik (915)
- Frankfurt Institute for Advanced Studies (FIAS) (856)
- Informatik (822)
- Medizin (5)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- ELEMENTS (1)
- Georg-Speyer-Haus (1)
- Gesellschaftswissenschaften (1)
Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM cells at specific time points: at diagnosis and before and after autologous stem cell transplantation. Remarkably, after cytokine stimulation, the patients' NK cells did not significantly differ from those of healthy donors. In a small cohort of MM patients, we were able to isolate autologous tumor cells, and we could demonstrate that IL-2/15 stimulated autologous NK cells were able to significantly improve their killing capacity of autologous tumor cells. With the aim to further improve the NK cell killing capacity against MM cells, we investigated the potential use of NK specific check point inhibitors with focus on NKG2A because this inhibitory NK cell receptor was upregulated following ex vivo cytokine stimulation and MM cells showed HLA-E expression that could even be increased by exposure to IFN-γ. Importantly, blocking of NKG2A resulted in a significant increase in the NK cell-mediated lysis of different MM target cells. Finally, these results let suggest that combining cytokine induced NK cell activation and the specific check point inhibition of the NKG2A-mediated pathways can be an effective strategy to optimize NK cell therapeutic approaches for treatment of multiple myeloma.
To assess the scope of infection control measures for multidrug-resistant bacteria in high-risk settings, a survey among university hospitals was conducted. Fourteen professionals from 8 sites participated. Reported policies varied largely with respect to the types of wards conducting screening, sample types used for screening and implementation of contact precautions. This variability among sites highlights the need for an evidence-based consensus of current infection control policies.
Simple Summary: Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values.
Abstract: Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.